clinicalomicsprowebdirectory
News
Topics
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Magazine
Marketplace
Multimedia
Webinars
eBooks
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Search
Advertise
Magazine Advertising
Website Banner Advertising
eNewsletter Advertising
Lead Generation Campaigns
Email Nurture Campaigns
Custom Content Solutions
About Us
Contact Us
Mary Ann Liebert Publishers
Create a Free Account
Log In
Clinical OMICs – Molecular Diagnostics in Precision Medicine
News
Molecular Dx
Genetic Mutation Discovery Could Lead to New Cardiovascular Treatments
Next-Generation Sequencing
Sequencing Alone Inaccurate for Detecting Rare Metabolic Diseases in Newborns
Diabetes
Babies’ Combined Risk Score Can Predict Type 1 Diabetes
Volume 7, Issue No. 4, July/August 2020
Building a COVID-19 Pop-Up Testing Lab
Molecular Dx
FDA Approves First NGS-Based Liquid Biopsy Companion Diagnostic
Topics
All
Precision Medicine
Translational Research
Molecular Dx
Informatics
Oncology
Patient Care
New Products
Molecular Dx
Genetic Mutation Discovery Could Lead to New Cardiovascular Treatments
Next-Generation Sequencing
Sequencing Alone Inaccurate for Detecting Rare Metabolic Diseases in Newborns
Diabetes
Babies’ Combined Risk Score Can Predict Type 1 Diabetes
Volume 7, Issue No. 4, July/August 2020
Building a COVID-19 Pop-Up Testing Lab
Magazine
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 3
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 2
Magazine
Clinical OMICs Magazine Volume 7, Issue No. 1
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 6
Magazine
Clinical OMICs Magazine Volume 6, Issue No. 5
Marketplace
Multimedia
All
Webinars
eBooks
Multimedia
Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials
Multimedia
Sequencing Controls Improve Confidence in NGS Patient Results
Bioinformatics
Advanced AI Technology for Clinical Genomic Support Across All Stages of…
Precision Medicine
RNA, Data Science, and the Future of Precision Medicine
Subscribe
Create a Free Account
Log In
Get Clinical OMICs Magazine
Get Clinical OMICs eNewsletters
Get the Clinical OMICs Mobile App
Get Clinical OMICs News from Alexa
Home
Biomarkers
Circulating Tumor Cell
Circulating Tumor Cell
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Circulating Tumor Cell
Tapping into the Potential of Circulating Tumor Cells
March 19, 2020
Circulating Tumor Cell
Microfluidic Chip Captures More than 99% of CTCs
May 18, 2019
Circulating Tumor Cell
Single-Cell Analysis of CTCs Improved via New Capture Technology
May 16, 2019
Circulating Tumor Cell
Providence St. Joseph Health, 2 Affiliates to Study Using CSF with...
February 27, 2019
Circulating Tumor Cell
Circulating Tumor Cells Isolated Efficiently with New Microfluidic Device
February 26, 2019
Circulating Tumor Cell
Medigen to Use CellMax Life CTC Blood Test in Trials of...
January 2, 2019
Circulating Tumor Cell
Sysmex, MolecularMD Partner on Precision Medicine Companion Diagnostics
November 29, 2018
Circulating Tumor Cell
Epic Sciences, Four Canadian Breast Cancer Centers Launch Trial of Blood...
November 5, 2018
Circulating Tumor Cell
Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient Selection
September 24, 2018
Circulating Tumor Cell
BMS to Use Natera’s Signatera ctDNA Assay in Adjuvant Opdivo NSCLC...
September 14, 2018
Load more
Scroll Up
We use cookies to give you a better experience on clinicalomics.com. By continuing to use our site, you are agreeing to the use of cookies as set in our
privacy policy.
Got it!
Edit with Live CSS
![Sysmex and MolecularMD will partner to develop and commercialize companion diagnostics for precision medicines through a master collaboration agreement whose value was not disclosed.[© Alex Tihonov/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/2029-324x160.jpeg "Sysmex, MolecularMD Partner on Precision Medicine Companion Diagnostics")
![Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1907-324x160.jpeg "Study Shows Epic Sciences Liquid Biopsy Aids Prostate Cancer Patient Selection")
![Bristol-Myers Squibb (BMS) plans to use Natera's Signatera custom circulating tumor DNA (ctDNA) assay in a Phase II study designed to assess the pharma giant’s cancer immunotherapy Opdivo (nivolumab) as an adjuvant treatment for non-small cell lung cancer (NSCLC). [Source: Eraxion/Getty]](https://www.clinicalomics.com/wp-content/uploads/2019/01/1893-324x160.jpeg "BMS to Use Natera’s Signatera ctDNA Assay in Adjuvant Opdivo NSCLC Trial")
